Adverse events  · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).
1 finding from 1 review
Sputum: volume · adults and children with cystic fibrosis
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes sputum volume (mL) compared with placebo (very low certainty).
1 finding from 1 review
FVC · adults, children and young people with CF
1 finding from 1 review
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
HRQoL ‐ change from baseline in CFCS total score and CFQ‐R respiratory domain · children and young adults with CF
1 finding from 1 review
FEV1 · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and young adults with CF
1 finding from 1 review
FVC (% predicted) Change from baseline · children and young adults with CF
1 finding from 1 review
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · children and young adults with CF
1 finding from 1 review
Lung function: FEV1 mL (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEV1 mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
FEV1 % predicted · children and young adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
FVC · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FVC mL (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
Lung function: FEF25‐75 mL/s (percentage change from baseline) · children and young adults with CF
It is very uncertain whether summary of findings ‐ Inhaled mannitol changes lung function: FEF25-75 mL/s (percentage change from baseline) compared with dornase alfa (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review